[Form 4] Aveanna Healthcare Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aveanna Healthcare (AVAH) — Form 4 insider transaction: On 10/24/2025, Director and 10% Owner Paul R. Vigano reported sales by affiliated entities pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares at $9; JHW Iliad Holdings LLC sold 224,553 shares at $9; and JHW Iliad Holdings II LLC sold 23,538 shares at $9.

Following these trades, reported indirect holdings include 19,292,787 shares via J.H. Whitney VII, L.P.; 15,523,809 via PSA Healthcare Investment Holdings LLC; 3,460,515 via JHW Iliad Holdings LLC; 1,426,034 via PSA Iliad Holdings LLC; and 362,746 via JHW Iliad Holdings II LLC.

Insights

Equity Ownership and Governance Analyst

Large shareholder/director sold shares via a secondary offering option; ownership remains significant across affiliated entities.

Paul R. Vigano (director and 10% owner) reported sales on 10/24/2025 by affiliated entities in an underwritten secondary offering option at $9 per share. Reported sales were 1,251,909 Shares by J.H. Whitney VII, L.P., 224,553 Shares by JHW Iliad Holdings LLC, and 23,538 Shares by JHW Iliad Holdings II LLC. No derivative transactions were reported.

After these transactions, the filing shows indirect beneficial ownership of 19,292,787 Shares via J.H. Whitney VII, L.P., 15,523,809 via PSA Healthcare Investment Holdings LLC, 1,426,034 via PSA Iliad Holdings LLC, and 3,460,515 via JHW Iliad Holdings LLC, plus 362,746 via JHW Iliad Holdings II LLC. Control relationships among entities are detailed, with standard disclaimers limiting beneficial ownership to pecuniary interests.

The mechanism is a selling stockholder transaction; proceeds accrue to selling entities, not the issuer. The disclosure signals continued substantial holdings despite sales. Items to watch include any subsequent Section 16 reports or Schedule 13D/13G updates reflecting changes in aggregate holdings, and any further activity tied to the underwritten secondary offering option around late October 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VIGANO PAUL R

(Last) (First) (Middle)

C/O J.H. WHITNEY CAPITAL PARTNERS, LLC

212 ELM STREET

(Street)

NEW CANAAN CT 06840

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aveanna Healthcare Holdings, Inc. [ AVAH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value								0	D(4)
Common Stock, $0.01 par value	10/24/2025		S(5)		1,251,909	D	$9	19,292,787	I	By J.H. Whitney VII, L.P.(1)
Common Stock, $0.01 par value								15,523,809	I	By PSA Healthcare Investment Holdings LLC(1)
Common Stock, $0.01 par value	10/24/2025		S(6)		224,553	D	$9	3,460,515	I	By JHW Iliad Holdings LLC(2)
Common Stock, $0.01 par value								1,426,034	I	By PSA Iliad Holdings LLC(1)
Common Stock, $0.01 par value	10/24/2025		S(7)		23,538	D	$9	362,746	I	By JHW Iliad Holdings II LLC(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. J.H. Whitney Equity Partners VII, LLC ("Equity Partners VII") is the general partner of J.H. Whitney VII, L.P. ("JHW VII") and Whitney Strategic Partners VII, L.P. ("Strategic Partners VII"). Strategic Partners VII is the managing member of each of PSA Healthcare Investment Holdings LLC ("PSA Healthcare") and PSA Iliad Holdings LLC ("PSA Iliad Holdings"). As a result, Equity Partners VII may be deemed to share voting and dispositive power with respect to shares of common stock, $0.01 par value per share (the "Shares"), held by each of JHW VII, PSA Healthcare and PSA Iliad Holdings, and Strategic Partners VII may be deemed to share voting and dispositive power with respect to the Shares held by each of PSA Healthcare and PSA Iliad Holdings. Each of Equity Partners VII and Strategic Partners VII disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

2. Project Iliad Managing Member, LLC ("Project Iliad") is the managing member of JHW Iliad Holdings LLC ("JHW Iliad"). As a result, Project Iliad may be deemed to share voting and dispositive power with respect to the Shares held by JHW Iliad. Project Iliad disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

3. J.H. Whitney Capital Partners, LLC ("Capital Partners") is the sole member of J.H. Whitney VII Management Co., LLC ("Management Co. VII"), which is the managing member of JHW Iliad Holdings II LLC ("JHW Iliad II," and, collectively with PSA Healthcare, JHW Iliad, and PSA Iliad Holdings, the "Stockholder Entities"). As a result, each of Capital Partners and Management Co. VII may be deemed to share voting and dispositive power with respect to the Shares held by JHW Iliad II. Each of Capital Partners and Management Co. VII disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

4. Paul R. Vigano is a Managing Member of Equity Partners VII, a Member of Project Iliad and a Senior Managing Director of Capital Partners. As a result, the undersigned may be deemed to share voting and dispositive power with respect to the Shares held by the Stockholder Entities. The undersigned disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

5. On October 24, 2025, J.H. Whitney VII, L.P sold 1,251,909 Shares pursuant to the option to purchase additional Shares in an underwritten secondary offering.

6. On October 24, 2025, JHW Iliad Holdings LLC sold 224,553 Shares pursuant to the option to purchase additional Shares in an underwritten secondary offering.

7. On October 24, 2025, JHW Iliad Holdings II LLC sold 23,538 Shares pursuant to the option to purchase additional Shares in an underwritten secondary offering.

	/s/ David Zatlukal, Attorney-in-Fact	10/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.